Updated hourlyHourly refreshWed, Sep 9, 2026
Press Release Database
Recent press releases, indexed by topic.
AI · Healthcare
(PR-inside.com) TORONTO, ON / ACCESS Newswire / September 2, 2026 / Datametrex AI Limited (the "Company" or "Datametrex'') (TSXV:DM)(FSE:D4G)(OTC PINK:DTMXF) is pleased to announce that it has initiated plans to wind down its health care operations. The wind-down is intended to allow the Company to focus its resources and management efforts on its core AI, data centre technology, and patent licensing businesses, optimize its current operations and resources, reduce operating and regulatory compliance requirements, and improve overall financial performance. As part of the wind-down process, the Company intends to gradually reduce and ultimately cease its health care operations, including the operation of its ..
Sep 2 · 12:00·PR-Inside
Healthcare
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (OTCQB: ESVNF) (the "Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, today announced that it has been approved to trade on the OTCQB Venture Market ("OTCQB") in the United States under the symbol "ESVNF", effective September 2, 2026. The Company also confirms that its common shares are eligible for electronic clearing and settlement through the...
Sep 2 · 12:00·mlpr-newsfile
Finance · Healthcare
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
Sep 2 · 12:00·GlobeNewswire
Finance · Healthcare
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:
Sep 2 · 12:00·GlobeNewswire
AI · Healthcare
Beginning October 1, 2026, hospitals using Bayesian's continuous sepsis monitor can receive additional Medicare reimbursement for eligible inpatient cases, the first reimbursement pathway of its kind for presuspicion sepsis monitoring. NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Bayesian...
Sep 2 · 11:54·PR Newswire
Finance · Healthcare
BOTHELL, Wash., September 02, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m.
Sep 2 · 11:45·mlpr-businesswire
Healthcare
LEOBENDORF, Austria, September 02, 2026--Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation.
Sep 2 · 11:37·mlpr-businesswire
Finance · Healthcare
Raanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).
Sep 2 · 11:32·GlobeNewswire
Finance · Healthcare
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
Sep 2 · 11:30·GlobeNewswire
SaaS · Healthcare
SOUTH SAN FRANCISCO, Calif., September 02, 2026--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that new results from the POLARIS clinical program of ETX101, its investigational AAV9-based gene regulation therapy for SCN1A+ Dravet syndrome, will be featured in a platform presentation at the 16th European Epilepsy Congress on September 7, 2026, in Athens, Greece.
Sep 2 · 11:30·mlpr-businesswire
Finance · SaaS
REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use. The patent allowance further expands the Company's intellectual property portfolio supporting its proprietary CAPTN-3 platform for conditionally activated multispecific antibodies.
Sep 2 · 11:30·GlobeNewswire
Finance · AI
Experienced pharmaceutical and healthcare executive joins advisory board to help accelerate innovation and strengthen life sciences marketing technology Experienced pharmaceutical and healthcare executive joins advisory board to help accelerate innovation and strengthen life sciences marketing technology
Sep 2 · 11:30·GlobeNewswire